en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 95
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
streszczenie artykułu:
Artykuł oryginalny

Intestinal microbiota in nephrotic children treated with immunosuppressive agents

Robert Szlachciński
1
,
Aleksandra Szlachcińska
2
,
Łukasz Szlachciński
3
,
Iwona Borycz-Stevens
4
,
Feras Almeer
5
,
Marcin Tkaczyk
4, 6

  1. Department of Neonatology, Tomaszow Health Center, Tomaszow Mazowiecki, Poland
  2. Department of Thoracic Surgery and Respiratory Rehabilitation, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
  3. Department of Anesthesiology and Intensive Therapy, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  4. Department of Paediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  5. Department of Obstetrics, Perinatology and Gynecology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  6. Division of Didactics in Pediatrics, Medical University of Lodz, Lodz, Poland
Pediatr Pol 2020; 95 (1): 6–13
DOI: https://doi.org/10.5114/polp.2020.94910
Data publikacji online: 2020/03/31
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Aim of the study
The analysis of the effect of immunosuppressive therapy on gut microbiota in pediatric patients with stable idiopathic nephrotic syndrome (INS) treated with different protocols of immunosuppressive therapy and examined the changes in their gut microbiota components along with accompanying clinical symptoms.

Material and methods
The study consisted of 44 children with INS divided into 3 groups according to treatment protocols (group A: 18 children on cyclosporine A [CsA], 9 of which receiving additional glucocorticosteroids [GCS]; group B: 17 children on GCS; and group C: 9 children on cyclophosphamide [CYC] and GCS), along with 20 healthy children serving as controls. Intestinal microflora was analysed with microbiological diagnostics based on KyberStatus and KyberMyk tests. Additional laboratory blood and urine tests were performed along with history data and clinical symptoms analysis. Study was approved by local Ethical Committee. All caregivers gave an informed consent for participation.

Results
Total number of bacterial colonies was significantly lower in group A (p < 0.001) and group B children (p = 0.04) when compared to the healthy controls. Group C children had a significantly lower number of Bifidobacterium colonies than the controls (p = 0.01), while number of Candida colonies were significantly higher in group A subjects than in controls (p = 0.01). No significant correlation between clinical symptoms reported by patients and the therapy used was found. Degree of disbiosis did was not related to the patients’ complaints either.

Conclusions
Immunosuppressed INS paediatric patients who are in remission had significantly unfavourable changes in their intestinal microbiota. Patient on chronic CsA therapy showed higher degree of dysbiosis.